Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma

Diffuse large B cell lymphoma (dlbcl) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40% will experience refractory disease after initial treatment, or relapse after a period of remission. In elig...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Curr Oncol
Asıl Yazarlar: Skrabek, P., Assouline, S., Christofides, A., MacDonald, D., Prica, A., Sangha, R., Matthews, B.A., Sehn, L.H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Multimed Inc. 2019
Konular:
Review Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726277/
https://ncbi.nlm.nih.gov/pubmed/31548805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.5421
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller